BrightSpring Health Services, I (BTSG) Stock Analysis
Healthcare · Health Information Services
Sell if holding. Analyst target reached at $57.40 — A.R:R is negative (-0.3) — price has exceeded the analyst target. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Concentration risk — Geographic: top-10 states (53.0%).
BrightSpring Health Services delivers home and community-based healthcare across Pharmacy Solutions (specialty/infusion/home dispensing, 43M+ prescriptions in 2025) and Provider Services (home health, hospice, rehab) segments, serving 465,000+ patients daily in all 50 states.... Read more
Sell if holding. Analyst target reached at $57.40 — A.R:R is negative (-0.3) — price has exceeded the analyst target. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Concentration risk — Geographic: top-10 states (53.0%). Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Score 5.6/10, moderate confidence.
Passes 6/8 gates (positive momentum, clean insider activity, no SEC red flags, earnings proximity 74d clear, semi cycle peak clear, materials cycle peak clear). Fails on favorable risk/reward ratio and news legal. Suitability: aggressive.
Recent Developments — BrightSpring Health Services, I
Latest news
- Centers For Medicare & Medicaid Services Announces Six-Month Moratoria On Hospice And Home Health Agency Registrations, — benzinga May 13, 2026 negative
- Watching BrightSpring Health Services; Hearing Popular Retail Traders Newsletter Mentions Stock As A Buy — benzinga May 12, 2026 positive
- Morgan Stanley Maintains Overweight on BrightSpring Health, Raises Price Target to $62 — benzinga May 6, 2026 positive
- Wells Fargo Maintains Overweight on BrightSpring Health, Raises Price Target to $61 — benzinga May 4, 2026 positive
- TD Cowen Maintains Buy on BrightSpring Health, Raises Price Target to $65 — benzinga May 4, 2026 positive
Generated 2026-05-20T21:06:21Z.
Thesis
Key Metrics
Quality Signals
Concentration Risks(10-K Item 1A)
- HIGHGeographictop-10 states53%10-K Item 1: 'approximately 53% of our revenue in 10 states for the year ended December 31, 2025'
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer
Rating Breakdown
1 ceiling hit
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Analyst target reached at $57.40 — A.R:R is negative (-0.3) — price has exceeded the analyst target. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Concentration risk — Geographic: top-10 states (53.0%). Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Prior stop was $53.40. Score 5.6/10, moderate confidence.
Take-profit target: $57.82 (+0.7% upside). Prior stop was $53.40. Stop-loss: $53.40.
Concentration risk — Geographic: top-10 states (53.0%); Analyst target reached - limited upside remaining; Near 52-week high (2.1% away).
BrightSpring Health Services, I trades at a P/E of 75.2 (forward 27.4). TrendMatrix value score: 5.2/10. Verdict: Sell.
22 analysts cover BTSG with a consensus score of 4.3/5. Average price target: $61.
What does BrightSpring Health Services, I do?BrightSpring Health Services delivers home and community-based healthcare across Pharmacy Solutions...
BrightSpring Health Services delivers home and community-based healthcare across Pharmacy Solutions (specialty/infusion/home dispensing, 43M+ prescriptions in 2025) and Provider Services (home health, hospice, rehab) segments, serving 465,000+ patients daily in all 50 states. Revenue is primarily Medicare and Medicaid reimbursement with ~53% from 10 states. The March 2026 divestiture of the Community Living business for $835M sharpens focus on Senior and Specialty patient pharmacy and clinical care.